Biotech company Amarantus BioSciences focuses on the development of new treatments for brain-related disorders such as Parkinson’s disease and traumatic brain injuries (TBI). The company’s efforts extend beyond the walls of a laboratory and spill onto the turf of many neurological injuries: the football field.
Earlier this year, ESPN reported that NFL players are at an unusually high risk of developing neurodegenerative diseases such as Parkinson’s disease due to the traumatic impact of multiple concussions and sub-concussive hits. This information hits particularly close to home with former Minnesota Vikings Pro Bowl linebacker E.J. Henderson, who supports further development of the Amarantus’ TBI research collaboration with Banyan Biomarkers.
“Concussions and their long-term side effects are a huge problem for NFL players and alumni,” Henderson stated in the press release. “I have been following Amarantus since they announced their collaboration with Banyan last November, and I was impressed with the initial success achieved this summer. As a result, I’ve decided to become actively involved with Amarantus in order to help bring their research to the forefront in the mainstream media. I believe these types of advances in scientific research can ultimately help current NFL players and NFL alumni who are at an unusually high risk of developing long-term side effects from multiple concussions.”
As part of his partnership with Amarantus, Henderson will work with NFL veterans Jack Brewer and Corey Chavous to raise awareness and support for Amarantus-Banyan research by utilizing the Coalition for Concussion Treatment (#C4CT) awareness campaign on Twitter, led by Brewer Sports International.
“NFL players are well aware of the risks associated with their sport, being directly affected by traumatic brain injuries on a daily basis. Many are taking an active role in supporting pertinent and relevant scientific research such as the research undertaken here at Amarantus,” said Gerald Commissiong, president & CEO of Amarantus and former professional football player with the Calgary Stampeders of the Canadian Football League. “E.J. Henderson understands the potential value and long-term benefits that our research effort could have for football players and their families. The awareness generated by the support of known athletes for our program should contribute to Amarantus’ growth, allowing us to attract capital to pursue our mission of developing new treatments for patients with brain disorders such as Parkinson’s and TBI.”
In June 2012, Amarantus announced positive data for its TBI collaboration with Banyan Biomarkers. The companies are currently working on the design of the next phase of testing Amarantus’ proprietary anti-apoptotic therapeutic protein, MANF, as a disease-modifying treatment for TBI.
For more information visit www.Amarantus.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment